EGFR and non-small cell lung carcinoma: Not least due to the entanglement of these two pathways, therapies that reverse immune tolerance through the blockade PD-1/PD-L1 and CTLA4 have attracted major interest in clinical trials of NSCLC and other EGFR-related malignancies.